Back to Search
Start Over
Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data
- Source :
- Intensive Care Medicine. November, 2015, Vol. 41 Issue 11, p1931, 10 p.
- Publication Year :
- 2015
-
Abstract
- Purpose Systemic antifungal therapy (SAT) of invasive candidiasis needs to be initiated immediately upon clinical suspicion. Controversies exist about adequate time and potential harm of antifungal de-escalation (DE) in documented and suspected candidiasis in ICU patients. Our objective was to investigate whether de-escalation within 5 days of antifungal initiation is associated with an increase of the 28-day mortality in SAT-treated non-neutropenic adult ICU patients. Methods From the 835 non-neutropenic adults recruited in the multicenter prospective observational AmarCAND2 study, we selected the patients receiving systemic antifungal therapy for a documented or suspected invasive candidiasis in the ICU and who were still alive 5 days after SAT initiation. They were included into two groups according to the occurrence of observed SAT de-escalation before day 6. The average causal SAT de-escalation effect on 28-day mortality was evaluated by using a double robust estimation. Results Among the 647 included patients, early de-escalation at day 5 after antifungal initiation occurred in 142 patients (22 %), including 48 (34 %) patients whose SAT was stopped before day 6. After adjustment for the baseline confounders, early SAT de-escalation was the solely factor not associated with increased 28-day mortality (RR 1.12, 95 % CI 0.76-1.66). Conclusion In non-neutropenic critically ill adult patients with documented or suspected invasive candidiasis, SAT de-escalation within 5 days was not related to increased day-28 mortality but it was associated with decreased SAT consumption. These results suggest for the first time that SAT de-escalation may be safe in these patients.<br />Author(s): Sébastien Bailly [sup.1] [sup.2], Olivier Leroy [sup.3], Philippe Montravers [sup.4], Jean-Michel Constantin [sup.5], Hervé Dupont [sup.6], Didier Guillemot [sup.7], Olivier Lortholary [sup.8] [sup.9], Jean-Paul Mira [sup.10] [sup.11], Pierre-François Perrigault [...]
- Subjects :
- Merck & Company Inc.
Gilead Sciences Inc.
Pfizer Inc.
Medical research -- Analysis
Medicine, Experimental -- Analysis
Mortality -- France
Antifungal agents -- Analysis
Hospital patients -- Patient outcomes -- Care and treatment
Candidiasis -- Patient outcomes -- Care and treatment
Health care industry
Subjects
Details
- Language :
- English
- ISSN :
- 03424642
- Volume :
- 41
- Issue :
- 11
- Database :
- Gale General OneFile
- Journal :
- Intensive Care Medicine
- Publication Type :
- Academic Journal
- Accession number :
- edsgcl.724286633
- Full Text :
- https://doi.org/10.1007/s00134-015-4053-1